June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Biomarkers of macular neovascularisation activity using optical coherence tomography angiography in treated stable neovascular age related macular degeneration
Author Affiliations & Notes
  • Daren Hanumunthadu
    Royal Free London NHS Foundation Trust, London, London, United Kingdom
    NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Konstantinos Balaskas
    NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Daniela Florea
    NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Pearse Andrew Keane
    NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Adam M Dubis
    NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Tariq Aslam
    School of Pharmacy and Optometry, Faculty of Biology, Medicine and Health, Manchester Metropolitan University, Manchester, Greater Manchester, United Kingdom
    Manchester Royal Eye Hospital, Manchester, Manchester, United Kingdom
  • Praveen Patel
    NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Footnotes
    Commercial Relationships   Daren Hanumunthadu None; Konstantinos Balaskas Roche, Novartis, Code C (Consultant/Contractor), Roche, Novartis, Bayer, Apelis, Code F (Financial Support), Novartis, Bayer, Roche, Alimera, Heidelberg Engineering, Code R (Recipient); Daniela Florea None; Pearse Keane DeepMind, Roche, Novartis, Apellis, BitFount, Code C (Consultant/Contractor), Big Picture Medical, Code O (Owner), Heidelberg Engineering, Topcon, Allergan, Bayer, Code R (Recipient); Adam Dubis Deep Eye Gmbh, Code F (Financial Support), J109804GB, P143850GB, P143861GB, Code P (Patent); Tariq Aslam None; Praveen Patel Novartis, Bayer, Oxford Electronics, Roche, Code C (Consultant/Contractor), Bayer, Code F (Financial Support), Novartis, Bayer, Topcon, Heidelberg Engineering, Code R (Recipient)
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 2936 – F0089. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Daren Hanumunthadu, Konstantinos Balaskas, Daniela Florea, Pearse Andrew Keane, Adam M Dubis, Tariq Aslam, Praveen Patel; Biomarkers of macular neovascularisation activity using optical coherence tomography angiography in treated stable neovascular age related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2022;63(7):2936 – F0089.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Biomarkers of activity of macula neovascularisation (MNV) in those deemed stable with conventional structural optical coherence tomography (OCT) could help to determine the requirement for further treatment and their associated monitoring interval for further visits. The aim of this study was to describe features of disease activity of treated stable MNV due to neovascular age related macular degeneration (nAMD) using optical coherence tomography angiography (OCTA).

Methods : 32 eyes of 32 patients with nAMD were included in this prospective, observational study. These patients were undergoing treatment with aflibercept on a treat-and-extend regimen. They were identified as attending a 16-week interval treatment visit and had been assessed as clinically stable based on clinical evaluation (visual acuity assessment, clinical examination and structural OCT assessment). All patients then underwent macular OCT imaging and OCT angiography on the same day (Spectralis, Heidelberg Engineering, Heidelberg, Germany). These images were analysed by the Moorfields Eye Hospital Reading Centre, London, United Kingdom.

Results : Evaluation of structural OCT confirmed no evidence of subretinal or intraretinal edema, but presence of subretinal hyperreflective material (13, 40.6%), pigment epithelial detachment (31, 96.9%), outer retinal tubulation (10, 31.3%) and macula atrophy (19, 59.4%). 31/32 OCTA images were gradeable (1 had significant signal attenuation); 28/32 (87.5%) OCTA images were noted to have signal artefacts. The mean MNV size was 3.6 ± 4.6mm and 29 (93.5%) and 27 (87.1%) had detectable MNV blood flow. 29 (93.5.%) subjects had MNV maturity including 10 non-specific, 10 tangle, 3 deadtree and no medusa or seafan phenotypes. MNV halo and MNV central feeder vessel were noted in 18 (58.1%) and 19 (61.3%) of subjects respectively; only 1 (3.2%) subject was noted to have a MNV capillary fringe.

Conclusions : CNV blood flow is still detectable using OCTA in the majority of subjects in this study. The majority of MNV were of mature phenotype. OCTA features associated with this clinically stable MNV activity included MNV maturity, feeder vessel, halo and absence of capillary fringe. These features could be helpful as possible OCTA biomarkers of disease activity and help inform treatment decisions with anti-vascular endothelial growth factor agents.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×